Lipid-Nanoparticle-based drug delivery systems: Recent advancements for small molecules and nucleic acids

Overview

After more than 25 years of commercial use with almost 20 parenteral drug products, lipid nanoparticles (LNPs) are having a breakout moment due to their use with a range of COVID-19 vaccines in clinical development. Beyond pandemics, LNPs are now considered a gold standard drug delivery technology for gene and cell-based therapies as well as other nanomedicines. They are also being increasingly considered across application areas including anti-cancer agents and antibiotics, peptide and protein-based synthetic vaccines, ligand-targeted formulations and imaging contrast agents.

In this webinar, Evonik will review key delivery requirements and best-practices for the formulation development and manufacturing of LNP-based drug products. In particular, our expert speakers will discuss the delivery of small molecule drugs and of nucleic acid (NA)-based therapeutics.

Experts featuring this session

Dr. Jayaganesh Natarajan
R&D Director
Vita

Dr. Natarajan holds a Ph.D. from Nanyang Technological University (NTU) in Singapore and has been with Evonik Vancouver Laboratories (VAN) for the past 4.5 years. Jay is currently serving as the Director of R&D at VAN. He started his professional career with Sun Pharma and was instrumental in the commercial scale up of LipoDox. Thereafter, he held various positions with different centers and institutes of NTU albeit his focus always revolved around the research and development of nanomedicines, particularly lipid nanoparticles. For example, he successfully developed the first sustained release nanomedicine formulation for glaucoma therapy which is currently ongoing clinical trials. Jay is the author of ten peer-reviewed papers and an inventor on two patents.

Natalia Zisman
Manager Process Development
Vita

Natalia Zisman is a Manager of Process Development at Evonik Vancouver Laboratories, specializing in liposome and lipid nanoparticle drug delivery systems. She is responsible for facilitating technology transfer of customer projects from R&D to clinical manufacturing. Natalia has 20 years of experience in liposome/lipid nanoparticle drug delivery field and has worked in a number of local drug delivery companies prior to joining Evonik in 2014. She has been involved in all aspects of liposome manufacturing, starting from early stage formulation design, process development, scale-up and clinical manufacturing. Natalia holds undergraduate degree in Chemistry from University of British Columbia.